This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yoon, S. S. Articles by Tanabe, K. K. Search for Related Content PubMed PubMed Citation Articles by Yoon, S. S. Articles by Tanabe, K. K.

Surgical Treatment and Other Regional Treatments for Colorectal Cancer Liver Metastases

Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA

Correspondence: Kenneth K. Tanabe, M.D., Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Cox 626, 100 Blossom Street, Boston, Massachusetts 02114, USA. Telephone: 617-724-3868; Fax: 617-724-3895.

The liver is the most common site of distant metastasis from colorectal cancer. About one-fourth of patients with liver metastases from colorectal cancer have no other sites of metastasis and can be treated with regional therapies directed toward their liver tumors. Surgical resection of colorectal cancer liver metastases can result in a 24%-38% five-year survival, but only a minority of patients are candidates for resection. Other regional therapies such as cryosurgery, radiofrequency ablation, and hepatic intra-arterial chemotherapy may be offered to patients with unresectable but isolated liver metastases. The efficacy of these treatments is still being determined. For most patients with spread of metastatic colorectal cancer beyond the liver, systemic chemotherapy rather than regional therapy is a more appropriate option.

Key Words. Colorectal cancer • Liver neoplasm • Hepatectomy • Cryosurgery • Radiofrequency ablation • Intra-arterial infusion • Chemotherapy

This article has been cited by other articles:

				M. T. Lee, J. J. Kim, R. Dinniwell, J. Brierley, G. Lockwood, R. Wong, B. Cummings, J. Ringash, R. V. Tse, J. J. Knox, et al. Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases J. Clin. Oncol., April 1, 2009; 27(10): 1585 - 1591. [Abstract] [Full Text] [PDF]

				D.-M. Koh, G. Brown, Z. Meer, A. R. Norman, and J. E. Husband Diagnostic Accuracy of Rim and Segmental MRI Enhancement of Colorectal Hepatic Metastasis After Administration of Mangafodipir Trisodium Am. J. Roentgenol., February 1, 2007; 188(2): W154 - W161. [Abstract] [Full Text] [PDF]

				H.M. Pinedo and C.J. van Groeningen Emerging New Opportunities for Patients with Hepatic Metastases from Colorectal Cancer or Primary Hepatocellular Cancer Oncologist, February 1, 2001; 6(1): 12 - 13. [Full Text]

				H. R. Alexander Jr., D. L. Bartlett, and S. K. Libutti Current Status of Isolated Hepatic Perfusion With or Without Tumor Necrosis Factor for the Treatment of Unresectable Cancers Confined to Liver Oncologist, October 1, 2000; 5(5): 416 - 424. [Abstract] [Full Text]